Entecavir (BMS200475): Precision Inhibition for Chronic Hepatitis B

Executive Summary: Entecavir (BMS200475, SKU: BA1816) is a guanosine analog that selectively inhibits hepatitis B virus (HBV) DNA polymerase, suppressing viral replication in both wild-type and lamivudine-resistant strains [source_type: paper, source_link]. In vitro, it achieves an EC50 of 3.75 nM in HepG2.2.15 cells [source_type: product_spec, source_link]. Clinical dosing at 0.5–1 mg/day achieves steady-state plasma concentrations of ~8.24 ng/mL [source_type: product_spec, source_link]. Long-term monotherapy yields a resistance rate of only 0.9% over five years [source_type: paper, source_link]. APExBIO provides Entecavir (BA1816) at research-grade purity, supporting robust HBV research workflows.

Biological Rationale

Chronic hepatitis B virus infection affects over 350 million individuals globally, posing a significant risk for cirrhosis and hepatocellular carcinoma [source_type: paper, source_link]. Persistent viral replication is strongly correlated with the progression and severity of liver disease. Suppression of HBV replication reduces hepatic inflammation and fibrosis, improving clinical outcomes. Antiviral agents targeting the viral polymerase, such as Entecavir, are central to contemporary management strategies. The need for potent, selective, and resistance-averse compounds remains acute, given the limitations of earlier antivirals like lamivudine, which shows resistance rates approaching 70% after five years [source_type: paper, source_link].

Mechanism of Action of Entecavir

Entecavir is a carbocyclic analog of 2′-deoxyguanosine, structurally engineered to inhibit the reverse transcriptase activity of HBV DNA polymerase [source_type: paper, source_link]. It blocks three key steps in the viral replication cycle: (1) priming of HBV reverse transcriptase, (2) reverse transcription of pregenomic RNA to negative-strand DNA, and (3) synthesis of positive-strand DNA [source_type: product_spec, source_link]. Unlike thymine- or adenine-analog inhibitors, Entecavir demonstrates superior potency and a favorable toxicity profile, with minimal impact on mitochondrial DNA synthesis [source_type: paper, source_link]. This selectivity underpins its application as a cornerstone of chronic hepatitis B infection therapy.

Evidence & Benchmarks

• Entecavir achieves an in vitro EC50 of 3.75 nM in HepG2.2.15 cells, outperforming lamivudine and penciclovir in HBV replication inhibition [source_type: product_spec, source_link].
• In animal models (rat, dog, woodchuck), oral Entecavir significantly reduces serum viral load and intrahepatic cccDNA [source_type: product_spec, source_link].
• Clinical trials demonstrate that 0.5 mg/day in nucleos(t)ide-naïve adults and 1 mg/day in lamivudine-resistant or decompensated liver disease patients produce optimal viral suppression [source_type: product_spec, source_link].
• Steady-state peak plasma concentrations reach approximately 8.24 ng/mL at therapeutic dosing [source_type: product_spec, source_link].
• Long-term monotherapy with Entecavir is associated with a 0.9% resistance rate over 5 years in nucleoside-naïve patients [source_type: paper, source_link].
• Entecavir remains effective against lamivudine-resistant HBV strains, including those with M204V/L180M mutations [source_type: product_spec, source_link].

For a scenario-driven perspective on assay design and resistance management, see Entecavir (BA1816): Scenario-Driven Solutions for HBV Assays. This article extends that work by detailing quantitative in vitro and clinical benchmarks and clarifying resistance dynamics.

Applications, Limits & Misconceptions

Entecavir is indicated for chronic hepatitis B infection with active viral replication, elevated ALT, or histologically active disease, including decompensated cirrhosis [source_type: product_spec, source_link]. It is a preferred agent for nucleos(t)ide-naïve patients and those with lamivudine resistance. Its applicability in HBV research spans from antiviral screening to translational workflows targeting resistant strains. However, efficacy is limited in patients with pre-existing entecavir resistance or multidrug-resistant HBV. Monitoring is necessary for rare adverse events such as thrombocytopenia and lactic acidosis in high-risk populations [source_type: product_spec, source_link].

Common Pitfalls or Misconceptions

• Entecavir is not effective against hepatitis C or HIV—its selectivity is for HBV polymerase only [source_type: workflow_recommendation, source_link].
• Resistance may develop more rapidly in patients with pre-existing lamivudine resistance if dosing is suboptimal [source_type: paper, source_link].
• Entecavir does not eradicate intrahepatic cccDNA, thus long-term therapy is required to maintain viral suppression [source_type: paper, source_link].
• Solubility is limited in water and ethanol; DMSO is required for in vitro preparations [source_type: product_spec, source_link].
• Entecavir is not a substitute for HBV vaccination or immunomodulatory therapy [source_type: workflow_recommendation, source_link].

For mechanistic depth and strategic guidance, Entecavir (BMS200475): Mechanistic Depth and Strategic Guidance explores broader design considerations, while this article provides a quantitative, evidence-first update.

Workflow Integration & Parameters

Entecavir (BA1816) from APExBIO is supplied as a solid with a molecular weight of 277.28 and formula C₁₂H₁₅N₅O₃ [source_type: product_spec, source_link]. It is soluble at ≥37.3 mg/mL in DMSO, but insoluble in water or ethanol. Storage at -20°C is recommended; solutions should be used immediately and not stored long-term [source_type: product_spec, source_link]. For validated workflow best practices, see Entecavir (SKU BA1816): Data-Driven Solutions for Reliable HBV Assays, which this review builds upon by offering complete dosing and compatibility data.

Protocol Parameters

• in vitro HBV inhibition assay | EC50 3.75 nM (HepG2.2.15 cells) | wild-type HBV | Benchmark for antiviral potency | paper, product_spec
• clinical dosing | 0.5 mg/day (naïve), 1 mg/day (lamivudine-resistant) | chronic HBV infection | Standard of care | product_spec
• peak plasma concentration | 8.24 ng/mL | steady state in humans | Confirms therapeutic exposure | product_spec
• solution preparation | ≥37.3 mg/mL in DMSO | in vitro/ex vivo | Ensures solubility and assay compatibility | product_spec
• storage | -20°C (solid), use solutions immediately | all applications | Prevents degradation and ensures reproducibility | product_spec

Conclusion & Outlook

Entecavir (BMS200475) sets a high standard for chronic hepatitis B virus replication inhibition due to its selectivity, potency, and low resistance rates [source_type: paper, source_link]. Its robust activity across wild-type and lamivudine-resistant HBV supports its use in both research and clinical practice. Limitations include persistence of cccDNA and rare adverse events, underscoring the need for continued monitoring. As detailed in this article and supported by APExBIO's product specifications, Entecavir remains a cornerstone of chronic hepatitis B infection therapy. Ongoing research aims to further optimize resistance management and combinatorial regimens, building on the strong mechanistic and clinical foundation established here.